1 |
A. U. Borwankar, A. K. Dinin, J. R. Laber, A. Twu, B. K. Wilson, J. A. Maynard, T. M. Truskett, and K. P. Johnston, "Tunable equilibrium nanocluster dispersions at high protein concentrations", Soft Matter, 9, 1766 (2013).
DOI
|
2 |
N. Inoue, E. Takai, T. Arakawa, and K. Shiraki, "Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations", Mol. Pharm., 11, 1889 (2014).
DOI
|
3 |
Z. Guo, A. Chen, R. A. Nassar, B. Helk, C. Mueller, Y. Tang, K. Gupta, and A. M. Klibanov, "Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies", Pharm. Res., 29, 3102 (2012).
DOI
|
4 |
A. U. Borwankar, B. J. Dear, A. Twu, J. J. Hung, A. K. Dinin, B. K. Wilson, J. Yue, J. A. Maynard, T. M. Truskett, and K. P. Johnston, "Viscosity reduction of a concentrated monoclonal antibody with arginine.HCl and arginine.glutamate", Ind. Eng. Chem. Res., 55, 11225 (2016).
DOI
|
5 |
https://www.repligen.com/technologies/tangenx-tff/sius-single-use, September 21 (2020).
|
6 |
Y. Baek, N. Singh, A. Arunkumar, M. Borys, Z. J. Li, and A. L. Zydney, "Ultrafiltration behavior of monoclonal antibodies and Fc-fusion proteins: Effects of physical properties", Biotechnol. Bioeng., 114, 2057 (2017).
DOI
|
7 |
M. R. Stoner, N. Fischer, L. Nixon, S. Buckel, M. Benke, F. Austin, T. W. Randolph, and B. S. Kendrick, "Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations", J. Pharm. Sci., 93, 2332 (2004).
DOI
|
8 |
G. R. Bolton, A. W. Boesch, J. Basha, D. P. LaCasse, B. D. Kelley, and H. Acharya, "Effect of protein and solution properties on the donnan effect during the ultrafiltration of proteins", Biotechnol. Prog., 27, 140 (2011).
DOI
|
9 |
F. Miao, A. Velayudhan, E. DiBella, J. Shervin, M. Felo, M. Teeters, and P. Alred, "Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody", Biotechnol. Prog., 25, 964 (2009).
DOI
|
10 |
M. Teeters, D. Bezila, T. Benner, P. Alfonso, and P. Alred, "Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies", Biotechnol. Bioeng., 108, 1338 (2011).
DOI
|
11 |
Y. Baek, N. Singh, A. Arunkumar, A. Borwankar, and A. L. Zydney, "Mass balance model with donnan equilibrium accurately describes unusual pH and excipient profiles during diafiltration of monoclonal antibodies", Biotechnol. J., 14, 1800517 (2019).
DOI
|
12 |
C. Casey, T. Gallos, Y. Alekseev, E. Ayturk, and S. Pearl, "Protein concentration with single-pass tangential flow filtration (SPTFF)", J. Memb. Sci., 384, 82 (2011).
DOI
|
13 |
J. Dizon-Maspat, J. Bourret, A. D'Agostini, and F. Li, "Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production", Biotechnol. Bioeng., 109, 962 (2012).
DOI
|
14 |
Lg경제연구원, "차세대 바이오 의약품, 세포치료제 시장 현황과 전망" (2017).
|
15 |
L. Fernandez-Cerezo, A. C. M. E. Rayat, A. Chatel, J. M. Pollard, G. J. Lye, and M. Hoare, "The prediction of the operating conditions on the permeate flux and on protein aggregation during membrane processing of monoclonal antibodies", J. Memb. Sci., 596, 117606 (2020).
DOI
|
16 |
L. M. Weiner, R. Surana, and S. Wang, "Monoclonal antibodies: Versatile platforms for cancer immunotherapy", Nat. Rev. Immunol., 10, 317 (2010).
DOI
|
17 |
W. Wang, S. Singh, D. L. Zeng, K. King, and S. Nema, "Antibody structure, instability, and formulation", J. Pharm. Sci., 96, 1 (2007).
DOI
|
18 |
www.evaluate.com/PharmaWorldPreview2019, September 11 (2020).
|
19 |
한국수출입은행 해외경제연구소, "세계 바이오의약품산업 동향 및 전망" (2019).
|
20 |
A. Mehta, "Downstream Processing for Biopharmaceuticals Recovery", pp. 163-190, Springer, Berlin (2019).
|
21 |
R. van Reis and A. Zydney, "Bioprocess membrane technology", J. Memb. Sci., 297, 16 (2007).
DOI
|
22 |
T. H. Choi and H. B. Park, "Membrane and virus filter trends in the processes of biopharmaceutical production", Membr. J., 30, 9 (2020).
DOI
|
23 |
https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma-Aldrich/General_Information/2/pellicon3_30kd_cleanability_techbrief-tb1241en-mk.pdf (2017).
|
24 |
https://www.pall.com/content/dam/pall/biopharm/lit-library/non-gated/procedures/09.3090_USTR2433b_T_Series_Cassettes_Omega_IFU_EN.pdf, December 9 (2009).
|
25 |
https://www.emdmillipore.com/Web-CA-Site/en_CA/-/CAD/ShowDocument-Pronet?id=201501.131, March (2018).
|
26 |
http://tangenx.com/wp-content/uploads/2015/01/TX-ProStream-HD.pdf, January (2015).
|
27 |
https://www.zind-vt.com/pdfs/HyStream.pdf, January (2015).
|
28 |
https://shop.pall.com/us/en/biotech/tangential-flowfiltration/cassettes/zidgri78m0j, September 11 (2020).
|
29 |
https://www.sartorius.com/shop/medias/-datasheet-enData-Hydrosart-Ultraf-White-Silicone-SPC2063-e.pdf (2019).
|
30 |
www.sartorius-stedim.com, September 11 (2020).
|
31 |
https://shop.pall.com/us/en/biotech/tangential-flowfiltration/cassettes/zidgri78lp2, September 11 (2020).
|
32 |
https://shop.pall.com/us/en/biotech/tangential-flowfiltration/cassettes/zidgri78m0j, September 11 (2020).
|
33 |
https://www.repligen.com/technologies/tangenx-tff/pro-reusable, September 11 (2020).
|
34 |
A. Arunkumar, N. Singh, E. G. Schutsky, M. Peck, R. K. Swanson, M. C. Borys, and Z. J. Li, "Effect of channel-induced shear on biologics during ultrafiltration/diafiltration (UF/DF)", J. Memb. Sci., 514, 671 (2016).
DOI
|
35 |
https://www.emdmillipore.com/Web-CA-Site/en_CA/-/CAD/ShowDocument-Pronet?id=201306.4194, December (2018).
|
36 |
https://bioprocessintl.com/downstream-processing/filtration/integrity-testing-of-ultrafiltration-systemsfor-biopharmaceutical-applications-335646/, August 31 (2020).
|
37 |
https://www.emdmillipore.com/Web-US-Site/en_CA/-/USD/ShowDocument-Pronet?id=201306.11634, May (2017).
|
38 |
A. M. Scott, J. D. Wolchok, and L. J. Old, "Antibody therapy of cancer", Nat. Rev. Cancer, 12, 278 (2012).
DOI
|
39 |
A. L. Nelson, E. Dhimolea, and J. M. Reichert, "Development trends for human monoclonal antibody therapeutics", Nat. Rev. Drug Discov., 9, 767 (2010).
DOI
|
40 |
Y. Baek, D. Yang, and A. L. Zydney, "Development of a hydrodynamic cleaning cycle for ultrafiltration/diafiltration processes used for monoclonal antibody formulation", Ind. Eng. Chem. Res., 57, 16110 (2018).
DOI
|
41 |
Y. Baek and A. L. Zydney, "Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins", Current Opinion in Biotechnology, 53, 59 (2018).
DOI
|
42 |
https://www.emdmillipore.com/Web-PR-Site/en_CA/-/USD/ShowDocument-File?ProductSKU=MM_NFC9947&DocumentId=201306.4192.ProNet&DocumentType=UG&Language=EN&Country=NF&Origin=PDP, February (2019).
|
43 |
https://www.pall.com/content/dam/pall/biopharm/lit-library/non-gated/procedures/09.3100_USTR2453b_T_Series_Cassettes_Omega_Delta_IFU_EN.pdf, December 9 (2009).
|
44 |
https://www.pall.com/content/dam/pall/biopharm/lit-library/non-gated/procedures/11.7322_USTR2662(3)_T_Series_Cassettes_Delta_IFU_EN.pdf, August 11 (2011).
|
45 |
P. Ng, J. Lundblad, and G. Mitra, "Note: optimization of solute separation by diafiltration", Separation Science, 11, 499 (1976).
DOI
|
46 |
K. McKeage, "A review of CT-P13: An infliximab biosimilar", BioDrugs, 28, 313 (2014).
DOI
|
47 |
W. Du and A. M. Klibanov, "Hydrophobic salts markedly diminish viscosity of concentrated protein solutions", Biotechnol. Bioeng., 108, 632 (2011).
DOI
|
48 |
T. M. Scherer, "Cosolute effects on the chemical potential and interactions of an IgG1 monoclonal antibody at high concentrations", J. Phys. Chem. B, 117, 2254 (2013).
DOI
|
49 |
K. P. Johnston, J. A. Maynard, T. M. Truskett, A. U. Borwankar, M. A. Miller, B. K. Wilson, A. K. Dinin, T. A. Khan, and K. J. Kaczorowski, "Concentrated dispersions of equilibrium protein nanoclusters that reversibly dissociate into active monomers", ACS Nano, 6, 1357 (2012).
DOI
|